New results from a clinical trial evaluating the drug show positive results in reducing the risk of heart failure.
The slimming drug Tirzepatide reduced the risk of hospitalization by 38% or death in obese adults with heart failurecompared to a placebo, according to Eli Lilly.
The American pharmaceutical company gave to know the results of a phase 3 clinical trial of the drug in obese adults with a common type of heart failure.
The drug is marketed under the name Zepbound for weight loss and Mounjaro for diabetes. The use of Mounjaro was authorized in the European Union in 2022.
Tirzepatide too improved heart failure symptoms and physical limitations, the company said, and helped adults lose 15.7% of your body weight compared to just 2.2% for those taking a placebo.
They will continue to evaluate the results of the trial
The company stated that I would continue to evaluate the results of the trial and would present them to the regulatory agencies at the end of this year.
The trial included 731 participants from nine countries that received 5, 10, or 15 milligrams of Ttirzepatide, depending on what you can tolerate, or a placebo. The drug was administered once a week.
What is Tirzepatide?
La Tirzepatida It is one of the most popular anti-obesity medications and the type 2 diabetesfrom the same class as semaglutide, the active ingredient of the drugs Ozempic and Wegovy from Novo Nordisk.
Tirzepatide also mimics the hormone GIP (glucose-dependent insulinotropic polypeptide), which regulates blood glucose levels.
Semaglutide has been shown to reduces cardiovascular events such as stroke, myocardial infarction and death in adults with pre-existing conditions.
The European Medicines Agency last week approved a positive opinion on the expanding the use of Wegovy to include the prevention of serious cardiovascular problems in overweight adults and cardiovascular disease.
Los adverse side effects most common of tirzepatide were diarrhea, nausea, constipation and vomitingaccording to Eli Lilly, although the medication can also cause more serious side effects.
Helps people with obstructive sleep apnea
And recent study published in the ‘New England Journal of Medicine’ revealed that Tirzepatide also May help people suffering from obstructive sleep apneaa serious sleep disorder in which people stop breathing while sleeping.
However, the company noted that the production of the drug entails risks and uncertainties and that there are no guarantees that it will be approved for patients with heart failure.
Cost, a great barrier for patients
Experts have also warned that cost and access remain obstacles for the use of these medications best sellers for weight losswhich suffer from shortages due to their popularity.
Weight problems and obesity are increasing in EU stateswith an estimate of 52.7% of the EU adult population overweight in 2019, according to the bloc’s statistical office, Eurostat.
